ProCE Banner Activity

Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease

Slideset Download
Conference Coverage
Etavopivat improved sickle RBC health and markers of sickle cell disease and pathophysiology in this phase I clinical study.

Released: December 17, 2021

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo Inc

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation